Adjuvant trastuzumab for breast cancer
- 3 November 2005
- Vol. 331 (7524), 1035-1036
- https://doi.org/10.1136/bmj.331.7524.1035
Abstract
Footnotes Competing interests MC has had research support from Roche Pharmaceuticals, the manufacturer of herceptin, as well as being reimbursed for speaking at several conferences.Keywords
This publication has 6 references indexed in Scilit:
- Trastuzumab in the Treatment of Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.1983